Moody's Rating for Antisense Therapeutics

MOODY'S ANALYTICS RISK SCORE

8

Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Antisense Therapeutics Ltd. is a pharmaceutical drug discovery and development company. The company's products include ATL1102 for Multiple Sclerosis, ATL1102 for Asthma, ATL1103 for Growth and Sight Disorders and ATL1101 for Prostate Cancer. It operates through the following segments: ATL 1102 - Multiple Sclerosis, and ATL 1103 - Growth and Sight Disorders. The company was founded in November 13, 2000 and is headquartered in Toorak, Australia.